Lipoprotein (a) and cardiovascular risk: The show must go on

Current Medicinal Chemistry

Volumn 24, Issue 10, 2017, Pages 989-1006

  Katsiki, Niki ^a   Al Rasadi, Khalid ^b   Mikhailidis, Dimitri P ^c  

^a ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

^b SULTAN QABOOS UNIVERSITY HOSPITAL   (Oman)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Cardiac diseases; Cardiovascular risk; Lipoprotein (a); Non cardiac vascular diseases; Vascular risk factors

Indexed keywords

LIPOPROTEIN A; URIC ACID; LIPOPROTEIN;

ABDOMINAL AORTIC ANEURYSM; AGE; ALCOHOL CONSUMPTION; AORTIC VALVE STENOSIS; ARTERIAL STIFFNESS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY DISEASE; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY FAILURE; CROHN DISEASE; DEMENTIA; DYSLIPIDEMIA; ERECTILE DYSFUNCTION; ETHNICITY; FAMILY HISTORY; GENDER; HEART FAILURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; HYPERURICEMIA; INFLAMMATORY BOWEL DISEASE; ISCHEMIC HEART DISEASE; KIDNEY ARTERY STENOSIS; LIPOPROTEIN METABOLISM; METABOLIC SYNDROME X; MIGRAINE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PSORIASIS; RACE DIFFERENCE; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK REDUCTION; SECONDARY PREVENTION; SLEEP DISORDERED BREATHING; SMOKING; SYSTEMIC LUPUS ERYTHEMATOSUS; ULCERATIVE COLITIS; URIC ACID BLOOD LEVEL; METABOLISM; RISK FACTOR;

CARDIOVASCULAR DISEASES; HUMANS; LIPOPROTEINS; RISK FACTORS;

EID: 85021117306     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867324666170112111948     Document Type: Review

References (260)

1. Schmidt, K.; Noureen, A.; Kronenberg, F.; Utermann, G. Structure, function, and genetics of lipoprotein (a). J. Lipid Res., 2016, 57(8), 1339-1359.
2. Gudnason, V. Lipoprotein(a): a causal independent risk factor for coronary heart disease? Curr. Opin. Cardiol., 2009, 24(5), 490-495.
3. Genser, B.; Dias, K.C.; Siekmeier, R.; Stojakovic, T.; Grammer, T.; Maerz, W. Lipoprotein (a) and risk of cardiovascular diseasea systematic review and meta analysis of prospective studies. Clin. Lab., 2011, 57(3-4), 143-156.
4. Danesh, J.; Collins, R.; Peto, R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation, 2000, 102(10), 1082-1085.
5. Orho-Melander, M. Genetics of coronary heart disease: towards causal mechanisms, novel drug targets and more personalized prevention. J. Intern. Med., 2015, 278(5), 433-446.
6. Tehrani, D.M.; Wong, N.D. Cardiovascular disease risk assessment: review of established and newer modalities. Curr. Treat. Options Cardiovasc. Med., 2015, 17(12), 57.
7. Kullo, I.J.; Trejo-Gutierrez, J.F.; Lopez-Jimenez, F.; Thomas, R.J.; Allison, T.G.; Mulvagh, S.L.; Arruda-Olson, A.M.; Hayes, S.N.; Pollak, A.W.; Kopecky, S.L.; Hurst, R.T. A perspective on the New American College of Cardiology/American Heart Association guidelines for cardiovascular risk assessment. Mayo Clin. Proc., 2014, 89(9), 1244-1256.
8. Vlachopoulos, C.; Xaplanteris, P.; Aboyans, V.; Brodmann, M.; Cífková, R.; Cosentino, F.; De Carlo, M.; Gallino, A.; Landmesser, U.; Laurent, S.; Lekakis, J.; Mikhailidis, D.P.; Naka, K.K.; Protogerou, A.D.; Rizzoni, D.; Schmidt-Trucksäss, A.; Van Bortel, L.; Weber, T.; Yamashina, A.; Zimlichman, R.; Boutouyrie, P.; Cockcroft, J.; O'Rourke, M.; Park, J.B.; Schillaci, G.; Sillesen, H.; Townsend, R.R. The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation: Endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society. Atherosclerosis, 2015, 241(2), 507-532.
9. Hendrani, A.D.; Adesiyun, T.; Quispe, R.; Jones, S.R.; Stone, N.J.; Blumenthal, R.S.; Martin, S.S. Dyslipidemia management in primary prevention of cardiovascular disease: Current guidelines and strategies. World J. Cardiol., 2016, 8(2), 201-210.
10. Catapano, A.L.; Reiner, Z.; De Backer, G.; Graham, I.; Taskinen, M.R.; Wiklund, O.; Agewall, S.; Alegria, E.; Chapman, M.; Durrington, P.; Erdine, S.; Halcox, J.; Hobbs, R.; Kjekshus, J.; Filardi, P.P.; Riccardi, G.; Storey, R.F.; Wood, D. ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis, 2011, 217(1), 3-46.
11. Nordestgaard, B.G.; Chapman, M.J.; Ray, K.; Borén, J.; Andreotti, F.; Watts, G.F.; Ginsberg, H.; Amarenco, P.; Catapano, A.; Descamps, O.S.; Fisher, E.; Kovanen, P.T.; Kuivenhoven, J.A.; Lesnik, P.; Masana, L.; Reiner, Z.; Taskinen, M.R.; Tokgözoglu, L.; Tybjærg-Hansen, A. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur. Heart J., 2010, 31(23), 2844-2853.
12. Anthony, D.; George, P.; Eaton, C.B. Cardiac risk factors: biomarkers and genetic tests to determine cardiovascular risk. FP Essent., 2014, 421, 11-15.
13. Enkhmaa, B.; Anuurad, E.; Berglund, L. Lipoprotein (a): impact by ethnicity and environmental and medical conditions. J. Lipid Res., 2016, 57(7), 1111-1125.
14. Lippi, G.; Targher, G.; Salvagno, G.L.; Montagnana, M.; Franchini, M.; Guidi, G.C. Lipoprotein(a) and ageing. Clin. Lab., 2010, 56(9-10), 463-466.
15. Akita, H.; Matsubara, M.; Shibuya, H.; Fuda, H.; Chiba, H. Effect of ageing on plasma lipoprotein(a) levels. Ann. Clin. Biochem., 2002, 39(Pt 3), 237-240.
16. Derby, C.A.; Crawford, S.L.; Pasternak, R.C.; Sowers, M.; Sternfeld, B.; Matthews, K.A. Lipid changes during the menopause transition in relation to age and weight: the Study of Womens Health Across the Nation. Am. J. Epidemiol., 2009, 169(11), 1352-1361.
17. Berg, G.; Mesch, V.; Boero, L.; Sayegh, F.; Prada, M.; Royer, M.; Muzzio, M.L.; Schreier, L.; Siseles, N.; Benencia, H. Lipid and lipoprotein profile in menopausal transition. Effects of hormones, age and fat distribution. Horm. Metab. Res., 2004, 36(4), 215-220.
18. Xiong, Z.W.; Wahlqvist, M.L.; Ibiebele, T.I.; Biegler, B.M.; Balazs, N.D.; Xiong, D.W.; Lim, Y.L. Relationship between plasma lipoprotein (a), apolipoprotein (a) phenotypes, and other coronary heart disease risk factors in a Melbourne South Asian population. Clin. Biochem., 2004, 37(4), 305-311.
19. Prajapati, J.; Joshi, H.; Sahoo, S.; Virpariya, K.; Parmar, M.; Shah, K. AGE-related differences of novel atherosclerotic risk factors and angiographic profile among gujarati acute coronary syndrome patients. J. Clin. Diagn. Res., 2015, 9(6), OC05-OC09.
20. Forbang, N.I.; Criqui, M.H.; Allison, MA.; Ix, J.H.; Steffen, B.T.; Cushman, M.; Tsai, M.Y. Sex and ethnic differences in the associations between lipoprotein(a) and peripheral arterial disease in the Multi-Ethnic Study of Atherosclerosis. J. Vasc. Surg., 2016, 63(2), 453-458.
21. Frohlich, J.; Dobiásová, M.; Adler, L.; Francis, M. Gender differences in plasma levels of lipoprotein (a) in patients with angiographically proven coronary artery disease. Physiol. Res., 2004, 53(5), 481-486.
22. Málek, F.; Dvorák, J.; Skalníková, V.; Mates, M.; Kmonícek, P.; Vávrová, Z.; Neužil, P. Correlation of lipoprotein(a) with the extent of coronary artery disease in patients with established coronary atherosclerosis: gender differences. Eur. J. Prev. Cardiol., 2015, 22(5), 603-605.
23. Metcalf, P.A.; Sharrett, A.R.; Folsom, A.R.; Duncan, B.B.; Patsch, W.; Hutchinson, R.G.; Szklo, M.; Davis, CE.; Tyroler, H.A. African American-white differences in lipids, lipoproteins, and apolipoproteins, by educational attainment, among middle-aged adults: the Atherosclerosis Risk in Communities Study. Am. J. Epidemiol., 1998, 148(8), 750-760.
24. Wu, H.D.; Berglund, L.; Dimayuga, C; Jones, J.; Sciacca, R.R.; Di Tullio, M.R.; Homma, S. High lipoprotein(a) levels and small apolipoprotein(a) sizes are associated with endothelial dysfunction in a multiethnic cohort. J. Am. Coll. Cardiol, 2004, 43(10), 1828-1833.
25. Banerjee, D.; Wong, E.C.; Shin, J.; Fortmann, S.P.; Palaniappan, L. Racial and ethnic variation in lipoprotein (a) levels among asian indian and chinese patients. J. Lipids, 2011, 2011, 291954.
26. Sharma, A.; Kasim, M.; Joshi, P.H.; Qian, Z.; Krivitsky, E.; Akram, K.; Rinehart, S.; Vazquez, G.; Miller, J.; Rohman, M.S.; Voros, S. Abnormal lipoprotein(a) levels predict coronary artery calcification in Southeast Asians but not in Caucasians: use of noninvasive imaging for evaluation of an emerging risk factor. J. Cardiovasc. Transl. Res., 2011, 4(4), 470-476.
27. Ashavaid, T.F.; Kondkar, A.A.; Todur, S.P.; Dherai, A.J.; Morey, J.; Raghavan, R. Lipid, lipoprotein, apolipoprotein and lipoprotein(a) levels: reference intervals in a healthy Indian population. J. Atheroscler. Thromb., 2005, 12(5), 251-259.
28. Os, I.; Høieggen, A.; Larsen, A.; Sandset, P.M.; Djurovic, S.; Berg, K.; Os, A.; Birkeland, K.; Westheim, A. Smoking and relation to other risk factors in postmenopausal women with coronary artery disease, with particular reference to whole blood viscosity and beta-cell function. J. Intern. Med, 2003, 253(2), 232-239.
29. Bermingham, M.; Brock, K.; Tran, D.; Yau, J.; Tran-Dinh, H. Smoking and lipid cardiovascular risk factors in Vietnamese refugees in Australia. Prev. Med., 1999, 28(4), 378-385.
30. Minami, J.; Todoroki, M.; Yoshii, M.; Mita, S.; Nishikimi, T.; Ishimitsu, T.; Matsuoka, H. Effects of smoking cessation or alcohol restriction on metabolic and fibrinolytic variables in Japanese men. Clin. Sci., 2002, 103(2), 117-122.
31. Richard, F.; Marécaux, N.; Dallongeville, J.; Devienne, M.; Tiem, N.; Fruchart, J.C.; Fantino, M.; Zylberberg, G.; Amouyel, P. Effect of smoking cessation on lipoprotein A-I and lipoprotein A-I:A-II levels. Metabolism, 1997, 46(6), 711-715.
32. Bilen, O.; Kamal, A.; Virani, S.S. Lipoprotein abnormalities in South Asians and its association with cardiovascular disease: Current state and future directions. World J. Cardiol., 2016, 8(3), 247-257.
33. Moon, J.Y.; Kwon, H.M.; Kwon, S.W.; Yoon, S.J.; Kim, J.S.; Lee, S.J.; Park, J.K.; Rhee, J.H.; Yoon, Y.W.; Hong, B.K.; Rim, S.J.; Kim, H.S. Lipoprotein(a) and LDL particle size are related to the severity of coronary artery disease. Cardiology, 2007, 108(4), 282-289.
34. Montserrat-de la Paz, S.; Bermudez, B.; Naranjo, M.C.; Lopez, S.; Abia, R.; Muriana, F.J. Pharmacological effects of niacin on acute hyperlipemia. Curr. Med. Chem., 2016, 7(3), 1345-1353.
35. Boden, W.E.; Probstfield, J.L.; Anderson, T.; Chaitman, B.R.; Desvignes-Nickens, P.; Koprowicz, K.; McBride, R.; Teo, K.; Weintraub, W. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med., 2011, 365(24), 2255-2267.
36. Landray, M.J.; Haynes, R.; Hopewell, J.C.; Parish, S.; Aung, T.; Tomson, J.; Wallendszus, K.; Craig, M.; Jiang, L.; Collins, R.; Armitage, J. Effects of extended-release niacin with laropiprant in high-risk patients. N. Engl. J. Med., 2014, 371(3), 203-212.
37. Nicholls, S.J.; Ruotolo, G.; Brewer, H.B.; Wang, M.D.; Liu, L.; Willey, M.B.; Deeg, M.A.; Krueger, K.A.; Nissen, S.E. Evacetrapib alone or in combination with statins lowers lipoprotein(a) and total and small LDL particle concentrations in mildly hypercholesterolemic patients. J. Clin. Lipidol., 2016, 10(3), 519-527.e4.
38. Filippatos, T.D.; Klouras, E.; Barkas, F.; Elisaf, M. Cholesteryl ester transfer protein inhibitors: challenges and perspectives. Expert Rev. Cardiovasc. Ther., 2016, 14(8), 953-962.
39. Barter, P.J.; Rye, K.A. Cholesteryl ester transfer protein inhibition is not yet deadpro. Arterioscler. Thromb. Vasc. Biol., 2016, 36(3), 439-441.
40. Yadav, K.; Sharma, M.; Ferdinand, K.C. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons. Nutr. Metab. Cardiovasc. Dis., 2016, 26(10), 853-862.
41. Page, M.M.; Watts, G.F. Emerging PCSK9 inhibitors for treating dyslipidaemia: buttressing the gaps in coronary prevention. Expert Opin. Emerg. Drugs, 2015, 20(2), 299-312.
42. Wierzbicki, A.S.; Viljoen, A. Anti-sense oligonucleotide therapies for the treatment of hyperlipidaemia. Expert Opin. Biol. Ther., 2016, 16(9), 1125-1134.
43. Norata, G.D.; Ballantyne, C.M.; Catapano, A.L. New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs. Eur. Heart J., 2013, 34(24), 1783-1789.
44. Kostakou, P.; Hatzigeorgiou, G.; Kolovou, V.; Mavrogeni, S.; Kolovou, G. Lipoprotein (a) evolution: possible benefits and harm. Genetic and non-genetic factors influencing its plasma levels. Curr. Med. Chem., [In press].
45. Derosa, G.; D'Angelo, A.; Mugellini, A.; Pesce, R.M.; Fogari, E.; Maffioli, P. Evaluation of emerging biomarkers in cardiovascular risk stratification of hypertensive patients: a 2-year study. Curr. Med. Res. Opin., 2012, 28(9), 1435-1445.
46. Serban, C.; Nicola, T.; Mateescu, R.; Noveanu, L.; Susan, L.; Pacurari, A.; Caraba, A.; Romoşan, I.; Cristescu, A. Serum lipoprotein (a) levels in patients with arterial hypertension. Rev. Med. Chir. Soc. Med. Nat. Iasi, 2010, 114(3), 798-802.
47. Ghorbani, A.; Rafieian-Kopaei, M.; Nasri, H. Lipoprotein (a): More than a bystander in the etiology of hypertension? A study on essential hypertensive patients not yet on treatment. J. Nephropathol., 2013, 2(1), 67-70.
48. Nasri, H. Association of serum lipoprotein (a) with hypertension in diabetic patients. Saudi J. Kidney Dis. Transpl., 2008, 19(3), 420-427.
49. Catena, C.; Colussi, G.; Nait, F.; Capobianco, F.; Sechi, L.A. Plasma lipoprotein(a) levels and atherosclerotic renal artery stenosis in hypertensive patients. Kidney Blood Press. Res., 2015, 40(2), 166-175.
50. Ikkruthi, S.; Rajappa, M.; Nandeesha, H.; Satheesh, S.; Sundar, I.; Ananthanarayanan, P.H.; Harichandrakumar, K.T. Hyperhomocysteinemia and hyperlipoproteinemia (a) in obese South Indian men: an indication for increased cardiovascular risk. Acta Physiol. Hung., 2014, 101(1), 13-20.
51. Corsetti, J.P.; Ryan, D.; Rainwater, D.L.; Moss, A.J.; Zareba, W.; Block, R.C.; Sparks, C.E. Lp(a) and risk of recurrent cardiac events in obese postinfarction patients. Obesity (Silver Spring), 2008, 16(12), 2717-2722.
52. Yilmaz, M.; Biri, A.; Bukan, N.; Karakoç, A.; Sancak, B.; Törüner, F.; Paşaoǧlu, H. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome. Gynecol. Endocrinol., 2005, 20(5), 258-263.
53. Mora, S.; Lee, I.M.; Buring, J.E.; Ridker, P.M. Association of physical activity and body mass index with novel and traditional cardiovascular biomarkers in women. JAMA, 2006, 295(12), 1412-1419.
54. Wang, W.; Lee, E.T.; Alaupovic, P.; Blackett, P.; Blevins, K.S. Correlation between lipoprotein(a) and other risk factors for cardiovascular disease and diabetes in Cherokee Indians: the Cherokee Diabetes Study. Ann. Epidemiol., 2005, 15(5), 390-397.
55. Nakhjavani, M.; Morteza, A.; Esteghamati, A.; Khalilzadeh, O.; Zandieh, A.; Safari, R. Serum lipoprotein(a) levels are greater in female than male patients with type-2 diabetes. Lipids, 2011, 46(4), 349-356.
56. Boronat, M.; Saavedra, P.; Pérez-Martín, N.; López-Madrazo, M.J.; Rodríguez-Pérez, C.; Nóvoa, F.J. High levels of lipoprotein(a) are associated with a lower prevalence of diabetes with advancing age: results of a cross-sectional epidemiological survey in Gran Canaria, Spain. Cardiovasc. Diabetol., 2012, 11, 81.
57. Ye, Z.; Haycock, P.C.; Gurdasani, D.; Pomilla, C.; Boekholdt, S.M.; Tsimikas, S.; Khaw, K.T.; Wareham, N.J.; Sandhu, M.S.; Forouhi, N.G. The association between circulating lipoprotein(a) and type 2 diabetes: is it causal? Diabetes, 2014, 63(1), 332-342.
58. Singla, S.; Kaur, K.; Kaur, G.; Kaur, H.; Kaur, J.; Jaswal, S. Lipoprotein (a) in type 2 diabetes mellitus: Relation to LDL: HDL ratio and glycemic control. Int. J. Diabetes Dev. Ctries., 2009, 29(2), 80-84.
59. Smaoui, M.; Hammami, S.; Chaaba, R.; Attia, N.; Hamda, K.B.; Masmoudi, A.S.; Mahjoub, S.; Bousslama, A.; Farhat, M.B.; Hammami, M. Lipids and lipoprotein(a) concentrations in Tunisian type 2 diabetic patients; Relationship to glycemic control and coronary heart disease. J. Diabetes Complications, 2004, 18(5), 258-263.
60. Yun, J.S.; Lim, T.S.; Cha, S.A.; Ahn, Y.B.; Song, K.H.; Choi, J.A.; Kwon, J.; Jee, D.; Cho, Y.K.; Park, Y.M.; Ko, S.H. Lipoprotein(a) predicts the development of diabetic retinopathy in people with type 2 diabetes mellitus. J. Clin. Lipidol., 2016, 10(2), 426-433.
61. Senba, H.; Furukawa, S.; Sakai, T.; Niiya, T.; Miyake, T.; Yamamoto, S.; Ueda, T.; Torisu, M.; Minami, H.; Miyaoka, H.; Onji, M.; Tanaka, K.; Matsuura, B.; Tanigawa, T.; Hiasa, Y.; Miyake, Y. Serum lipoprotein(a) levels and diabetic nephropathy among Japanese patients with type 2 diabetes mellitus. J. Diabetes Complications, 2016, 30(5), 923-927.
62. Lin, J.; Reilly, M.P.; Terembula, K.; Wilson, F.P. Plasma lipoprotein(a) levels are associated with mild renal impairment in type 2 diabetics independent of albuminuria. PLos One, 2014, 9(12), e114397.
63. Gazzaruso, C.; Coppola, A.; Montalcini, T.; Baffero, E.; Garzaniti, A.; Pelissero, G.; Collaviti, S.; Grugnetti, A.; Gallotti, P.; Pujia, A.; Solerte, S.B.; Giustina, A. Lipoprotein(a) and homocysteine as genetic risk factors for vascular and neuropathic diabetic foot in type 2 diabetes mellitus. Endocrine, 2012, 41(1), 89-95.
64. Unlühizarci, K.; Muhtaroǧlu, S.; Kabak, S.; Bayram, F.; Keleştimur, F. Serum lipoprotein (a) levels in patients with diabetic foot lesions. Diabetes Res. Clin. Pract., 2006, 71(2), 119-123.
65. Jae, S.Y.; Heffernan, K.S.; Lee, M.K.; Fernhall, B.; Park, W.H. Relation of cardiorespiratory fitness to inflammatory markers, fibrinolytic factors, and lipoprotein(a) in patients with type 2 diabetes mellitus. Am. J. Cardiol., 2008, 102(6), 700-703.
66. Toro, R.; Segura, E.; Nuñez-Cortes, J.M.; Pedro-Botet, J.C.; Quezada-Feijoo, M.; Mangas, A. Relationship between lipoprotein (a) and micro/macro complications in type 2 diabetes mellitus: a forgotten target. J. Geriatr. Cardiol., 2015, 12(2), 93-99.
67. Chen, J.; Zhang, Y.; Liu, J.; Chen, M.H.; Guo, Y.L.; Zhu, C.G.; Xu, R.X.; Dong, Q.; Li, J.J. Role of lipoprotein(a) in predicting the severity of new on-set coronary artery disease in type 2 diabetics: A Gensini score evaluation. Diab. Vasc. Dis. Res., 2015, 12(4), 258-264.
68. Qi, Q.; Qi, L. Lipoprotein(a) and cardiovascular disease in diabetic patients. Clin. Lipidol., 2012, 7(4), 397-407.
69. Katsiki, N.; Tziomalos, K.; Mikhailidis, D.P. Alcohol and the cardiovascular system: a double-edged sword. Curr. Pharm. Des., 2014, 20(40), 6276-6288.
70. Gardner, J.D.; Mouton, A.J. Alcohol effects on cardiac function. Compr. Physiol., 2015, 5(2), 791-802.
71. Fernández-Solà, J. Cardiovascular risks and benefits of moderate and heavy alcohol consumption. Nat. Rev. Cardiol., 2015, 12(10), 576-587.
72. Hao, G.; Wang, Z.; Zhang, L.; Chen, Z.; Wang, X.; Guo, M.; Tian, Y.; Shao, L.; Zhu, M. Relationship between alcohol consumption and serum lipid profiles among middleaged population in china: a multiple-center cardiovascular epidemiological study. Angiology, 2015, 66(8), 753-758.
73. Chiva-Blanch, G.; Urpi-Sarda, M.; Ros, E.; Valderas-Martinez, P.; Casas, R.; Arranz, S.; Guillén, M.; Lamuela-Raventós, R.M.; Llorach, R.; Andres-Lacueva, C.; Estruch, R. Effects of red wine polyphenols and alcohol on glucose metabolism and the lipid profile: a randomized clinical trial. Clin. Nutr., 2013, 32(2), 200-206.
74. Rouillier, P.; Bertrais, S.; Daudin, J.J.; Bacro, J.N.; Hercberg, S.; Boutron-Ruault, M.C. Drinking patterns are associated with variations in atherosclerotic risk factors in French men. Eur. J. Nutr., 2006, 45(2), 79-87.
75. Rakic, V.; Puddey, I.B.; Dimmitt, S.B.; Burke, V.; Beilin, L.J. A controlled trial of the effects of pattern of alcohol intake on serum lipid levels in regular drinkers. Atherosclerosis, 1998, 137(2), 243-252.
76. Papademetriou, V.; Katsiki, N.; Doumas, M.; Faselis, C. Halting arterial aging in patients with cardiovascular disease: hypolipidemic and antihypertensive therapy. Curr. Pharm. Des., 2014, 20(40), 6339-6349.
77. Doonan, R.J.; Hausvater, A.; Scallan, C.; Mikhailidis, D.P.; Pilote, L.; Daskalopoulou, S.S. The effect of smoking on arterial stiffness. Hypertens. Res., 2010, 33(5), 398-410.
78. Seifalian, A.M.; Filippatos, T.D.; Joshi, J.; Mikhailidis, D.P. Obesity and arterial compliance alterations. Curr. Vasc. Pharmacol., 2010, 8(2), 155-168.
79. Kozakova, M.; Palombo, C. Diabetes mellitus, arterial wall, and cardiovascular risk assessment. Int. J. Environ. Res. Public Health, 2016, 13(2), 201.
80. Sorokin, A.; Kotani, K. Lipoprotein(a) and arterial stiffness parameters. Pulse (Basel), 2015, 3(2), 148-152.
81. Wakabayashi, I.; Masuda, H. Lipoprotein (a) as a determinant of arterial stiffness in elderly patients with type 2 diabetes mellitus. Clin. Chim. Acta, 2006, 373(1-2), 127-131.
82. Morishita, R.; Ishii, J.; Kusumi, Y.; Yamada, S.; Komai, N.; Ohishi, M.; Nomura, M.; Hishida, H.; Niihashi, M.; Mitsumata, M. Association of serum oxidized lipoprotein(a) concentration with coronary artery disease: potential role of oxidized lipoprotein(a) in the vasucular wall. J. Atheroscler. Thromb., 2009, 16(4), 410-418.
83. Kotani, K.; Yamada, S.; Yamada, T.; Kario, K.; Taniguchi, N. Oxidized lipoprotein(a) and cardio-ankle vascular index (CAVI) in hypertensive subjects. Heart Vessels, 2013, 28(4), 461-466.
84. Schillinger, M.; Mlekusch, W.; Haumer, M.; Sabeti, S.; Maca, T.; Minar, E. Relation of small artery compliance and lipoprotein (a) in patients with atherosclerosis. Am. J. Hypertens., 2002, 15(11), 980-985.
85. Liu, Q.M.; Zhou, S.H.; Qi, S.S.; Zhao, S.P.; Minghuib, L. Significance of the lipid profile and endothelium-dependent vasodilatation in the pathogenesis of microvascular angina. Cardiol. J., 2008, 15(4), 324-328.
86. Wilmink, H.W.; de Kleijn, M.J.; Bots, M.L.; Bak, A.A.; van der Schouw, Y.T.; Engelen, S.; Planellas, J.; Banga, J.; Grobbee, D.E. Lipoprotein (a) is associated with endothelial function in healthy postmenopausal women. Atherosclerosis, 2000, 153(1), 249-254.
87. Katsiki, N.; Karagiannis, A.; Athyros, V.G.; Mikhailidis, D.P. Hyperuricaemia: more than just a cause of gout? J. Cardiovasc. Med. (Hagerstown), 2013, 14(6), 397-402.
88. Katsiki, N.; Mikhailidis, D.P. Hyperuricaemia in cardiovascular diseases: a passive or an active player? Med. Princ. Pract., 2015, 24(3), 269-270.
89. Lippi, G.; Montagnana, M.; Luca Salvagno, G.; Targher, G.; Cesare Guidi, G. Epidemiological association between uric acid concentration in plasma, lipoprotein(a), and the traditional lipid profile. Clin. Cardiol., 2010, 33(2), E76-E80.
90. Virani, S.S.; Brautbar, A.; Davis, B.C.; Nambi, V.; Hoogeveen, R.C.; Sharrett, A.R.; Coresh, J.; Mosley, T.H.; Morrisett, J.D.; Catellier, D.J.; Folsom, A.R.; Boerwinkle, E.; Ballantyne, C.M. Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation, 2012, 125(2), 241-249.
91. Gurdasani, D.; Sjouke, B.; Tsimikas, S.; Hovingh, G.K.; Luben, R.N.; Wainwright, N.W.; Pomilla, C.; Wareham, N.J.; Khaw, K.T.; Boekholdt, S.M.; Sandhu, M.S. Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk prospective population study. Arterioscler. Thromb. Vasc. Biol., 2012, 32(12), 3058-3065.
92. Erqou, S.; Kaptoge, S.; Perry, P.L.; Di Angelantonio, E.; Thompson, A.; White, I.R.; Marcovina, S.M.; Collins, R.; Thompson, S.G.; Danesh, J. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA, 2009, 302(4), 412-423.
93. Hopewell, J.C.; Clarke, R.; Parish, S.; Armitage, J.; Lathrop, M.; Hager, J.; Collins, R. Lipoprotein(a) genetic variants associated with coronary and peripheral vascular disease but not with stroke risk in the Heart Protection Study. Circ. Cardiovasc. Genet., 2011, 4(1), 68-73.
94. Kiechl, S.; Willeit, J.; Mayr, M.; Viehweider, B.; Oberhollenzer, M.; Kronenberg, F.; Wiedermann, C.J.; Oberthaler, S.; Xu, Q.; Witztum, J.L.; Tsimikas, S. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler. Thromb. Vasc. Biol., 2007, 27(8), 1788-1795.
95. Khan, T.Z.; Rhodes, S.; Pottle, A.; Banya, W.; Smith, R.; Kabir, T.; Ilsley, C.; Pennell, D.J.; Barbir, M. High prevalence of raised lipoprotein(a) in patients with refractory angina. Glob. Cardiol. Sci. Pract., 2015, 2015(2), 28.
96. Nishino, M.; Mori, N.; Yoshimura, T.; Nakamura, D.; Lee, Y.; Taniike, M.; Makino, N.; Kato, H.; Egami, Y.; Shutta, R.; Tanouchi, J.; Yamada, Y. Higher serum uric acid and lipoprotein(a) are correlated with coronary spasm. Heart Vessels, 2014, 29(2), 186-190.
97. Sundell, J.; Laine, H.; Raitakari, O.T.; Luotolahti, M.; Nuutila, P.; Viikari, J.; Knuuti, J. Increased lipoprotein(a) is associated with reduced myocardial vasoreactivity in young healthy men. Atherosclerosis, 2005, 179(1), 185-191.
98. Ashfaq, F.; Goel, P.K.; Moorthy, N.; Sethi, R.; Khan, M.I.; Idris, M.Z. Lipoprotein(a) and syntax score association with severity of coronary artery atherosclerosis in North India. Sultan Qaboos Univ. Med. J., 2012, 12(4), 465-472.
99. Habib, S.S.; Abdel-Gader, A.M.; Kurdi, M.I.; Al-Aseri, Z.; Soliman, M.M. Lipoproteina(a) is a feature of the presence, diffuseness, and severity of coronary artery disease in Saudi population. Saudi Med. J., 2009, 30(3), 346-352.
100. Boroumand, M.A.; Rekabi, V.; Davoodi, G.; Amirzadegan, A.; Saadat, S.; Abbasi, S.H.; Hamidian, R.; Poorgholi, L. Correlation between lipoprotein(a) serum concentration and severity of coronary artery stenosis in an Iranian population according to Gensini score. Clin. Biochem., 2008, 41(3), 117-120.
101. Guler, E.; Gecmen, C.; Guler, G.B.; Karaca, O.; Agus, H.Z.; Gunes, H.M.; Batgerel, U.; Elveran, A.; Esen, A.M. Adding lipoprotein(a) levels to the GRACE score to predict prognosis in patients with non-ST elevation acute coronary syndrome. Kardiol. Pol., 2013, 71(7), 695-701.
102. Nozue, T.; Yamamoto, S.; Tohyama, S.; Fukui, K.; Umezawa, S.; Onishi, Y.; Kunishima, T.; Sato, A.; Nozato, T.; Miyake, S.; Takeyama, Y.; Morino, Y.; Yamauchi, T.; Muramatsu, T.; Hibi, K.; Terashima, M.; Michishita, I. Lipoprotein(a) is associated with necrotic core progression of non-culprit coronary lesions in statin-treated patients with angina pectoris. Lipids Health Dis., 2014, 13, 59.
103. Hikita, H.; Shigeta, T.; Kojima, K.; Oosaka, Y.; Hishikari, K.; Kawaguchi, N.; Nakashima, E.; Sugiyama, T.; Akiyama, D.; Kamiishi, T.; Kimura, S.; Takahashi, Y.; Kuwahara, T.; Sato, A.; Takahashi, A.; Isobe, M. Lipoprotein(a) is an important factor to determine coronary artery plaque morphology in patients with acute myocardial infarction. Coron. Artery Dis., 2013, 24(5), 381-385.
104. Niccoli, G.; Chin, D.; Scalone, G.; Panebianco, M.; Abbolito, S.; Cosentino, N.; Jacoangeli, F.; Refaat, H.; Gallo, G.; Salerno, G.; Volpe, M.; Crea, F.; De Biase, L. Data on the lipoprotein (a), coronary atherosclerotic burden and vulnerable plaque phenotype in angiographic obstructive coronary artery disease. Data Brief, 2016, 7, 1409-1412.
105. Jug, B.; Papazian, J.; Lee, R.; Budoff, M.J. Association of lipoprotein subfractions and coronary artery calcium in patient at intermediate cardiovascular risk. Am. J. Cardiol., 2013, 111(2), 213-218.
106. Ahmadi, N.; Tsimikas, S.; Hajsadeghi, F.; Saeed, A.; Nabavi, V.; Bevinal, M.A.; Kadakia, J.; Flores, F.; Ebrahimi, R.; Budoff, M.J. Relation of oxidative biomarkers, vascular dysfunction, and progression of coronary artery calcium. Am. J. Cardiol., 2010, 105(4), 459-466.
107. Qasim, A.N.; Martin, S.S.; Mehta, N.N.; Wolfe, M.L.; Park, J.; Schwartz, S.; Schutta, M.; Iqbal, N.; Reilly, M.P. Lipoprotein(a) is strongly associated with coronary artery calcification in type-2 diabetic women. Int. J. Cardiol., 2011, 150(1), 17-21.
108. Guerra, R.; Yu, Z.; Marcovina, S.; Peshock, R.; Cohen, J.C.; Hobbs, H.H. Lipoprotein(a) and apolipoprotein(a) isoforms: no association with coronary artery calcification in the Dallas Heart Study. Circulation, 2005, 111(12), 1471-1479.
109. Safarova, M.S.; Ezhov, M.V.; Afanasieva, O.I.; Matchin, Y.G.; Atanesyan, R.V.; Adamova, I.Y.; Utkina, E.A.; Konovalov, G.A.; Pokrovsky, S.N. Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography. Atheroscler. Suppl., 2013, 14(1), 93-99.
110. Nestel, P.J.; Barnes, E.H.; Tonkin, A.M.; Simes, J.; Fournier, M.; White, H.D.; Colquhoun, D.M.; Blankenberg, S.; Sullivan, D.R. Plasma lipoprotein(a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease. Arterioscler. Thromb. Vasc. Biol., 2013, 33(12), 2902-2908.
111. O'Donoghue, M.L.; Morrow, D.A.; Tsimikas, S.; Sloan, S.; Ren, A.F.; Hoffman, E.B.; Desai, N.R.; Solomon, S.D.; Domanski, M.; Arai, K.; Chiuve, S.E.; Cannon, C.P.; Sacks, F.M.; Sabatine, M.S. Lipoprotein(a) for risk assessment in patients with established coronary artery disease. J. Am. Coll. Cardiol., 2014, 63(6), 520-527.
112. Kwon, S.W.; Kim, J.Y.; Sung, J.M.; Yoon, Y.W.; Rhee, J.H.; Lee, B.K.; Jung, Y.H.; Kim, K.H.; Cha, J.J.; Park, J.K.; Choi, E.Y.; Hong, B.K.; Rim, S.J.; Kwon, H.M. Elevated lipoprotein(a) has incremental prognostic value in type 2 diabetic patients with symptomatic coronary artery disease. J. Atheroscler. Thromb., 2015, 22(5), 527-534.
113. Ikenaga, H.; Ishihara, M.; Inoue, I.; Kawagoe, T.; Shimatani, Y.; Miura, F.; Nakama, Y.; Dai, K.; Otani, T.; Ejiri, K.; Oda, N.; Nakamura, M.; Miki, T. Usefulness of Lipoprotein (a) for predicting progression of non-culprit coronary lesions after acute myocardial infarction. Circ. J., 2011, 75(12), 2847-2852.
114. Park, S.H.; Rha, S.W.; Choi, B.G.; Park, J.Y.; Jeon, U.; Seo, H.S.; Kim, E.J.; Na, J.O.; Choi, C.U.; Kim, J.W.; Lim, H.E.; Park, C.G.; Oh, D.J. Impact of high lipoprotein(a) levels on in-stent restenosis and long-term clinical outcomes of angina pectoris patients undergoing percutaneous coronary intervention with drug-eluting stents in Asian population. Clin. Exp. Pharmacol. Physiol., 2015, 42(6), 588-595.
115. Qin, S.Y.; Liu, J.; Jiang, H.X.; Hu, B.L.; Zhou, Y.; Olkkonen, V.M. Association between baseline lipoprotein (a) levels and restenosis after coronary stenting: metaanalysis of 9 cohort studies. Atherosclerosis, 2013, 227(2), 360-366.
116. Konishi, H.; Miyauchi, K.; Kasai, T.; Tsuboi, S.; Ogita, M.; Naito, R.; Sai, E.; Fukushima, Y.; Katoh, Y.; Okai, I.; Tamura, H.; Okazaki, S.; Daida, H. Impact of lipoprotein(a) as residual risk on long-term outcomes in patients after percutaneous coronary intervention. Am. J. Cardiol., 2015, 115(2), 157-160.
117. Cai, A.; Li, L.; Zhang, Y.; Mo, Y.; Li, Z.; Mai, W.; Zhou, Y. Baseline LDL-C and Lp(a) elevations portend a high risk of coronary revascularization in patients after stent placement. Dis. Markers, 2013, 35(6), 857-862.
118. Fefer, P.; Tsimikas, S.; Segev, A.; Sparkes, J.; Otsuka, F.; Kolodgie, F.; Virmani, R.; Juliano, J.; Charron, T.; Strauss, B.H. The role of oxidized phospholipids, lipoprotein (a) and biomarkers of oxidized lipoproteins in chronically occluded coronary arteries in sudden cardiac death and following successful percutaneous revascularization. Cardiovasc. Revasc. Med., 2012, 13(1), 11-19.
119. Ezhov, M.V.; Safarova, M.S.; Afanasieva, O.I.; Kukharchuk, V.V.; Pokrovsky, S.N. Lipoprotein(a) level and apolipoprotein(a) phenotype as predictors of long-term cardiovascular outcomes after coronary artery bypass grafting. Atherosclerosis, 2014, 235(2), 477-482.
120. Harris, M.; Shammas, N.W.; Jerin, M. Elevated levels of low-density lipoprotein cholesterol, homocysteine, and lipoprotein(a) are associated with the occurrence of symptomatic bypass graft disease 1 year following coronary artery bypass graft surgery. Prev. Cardiol., 2004, 7(3), 106-108.
121. Pokrovsky, S.N.; Ezhov, M.V.; Ilina, L.N.; Afanasieva, O.I.; Sinitsyn, V.Y.; Shiriaev, A.A.; Akchurin, R.S. Association of lipoprotein(a) excess with early vein graft occlusions in middle-aged men undergoing coronary artery bypass surgery. J. Thorac. Cardiovasc. Surg., 2003, 126(4), 1071-1075.
122. Kunutsor, S.K.; Khan, H.; Nyyssönen, K.; Laukkanen, J.A. Lipoprotein(a) and risk of sudden cardiac death in middleaged Finnish men: A new prospective cohort study. Int. J. Cardiol., 2016, 220, 718-725.
123. Onat, A.; Can, G.; Çoban, N.; Dönmez, İ.; Çakir, H.; Ademoǧlu, E.; Erginel-Ünaltuna, N.; Yüksel, H. Lipoprotein(a) level and MIF gene variant predict incident metabolic syndrome and mortality. J. Investig. Med., 2016, 64(2), 392-399.
124. Ariyo, A.A.; Thach, C.; Tracy, R. Lp(a) lipoprotein, vascular disease, and mortality in the elderly. N. Engl. J. Med., 2003, 349(22), 2108-2115.
125. Katsiki, N.; Doumas, M.; Mikhailidis, D.P. Lipids, statins and heart failure: an update. Curr. Pharm. Des., 2016, 22(31), 4796-4806.
126. Kamstrup, P.R.; Nordestgaard, B.G. Elevated lipoprotein(a) levels, LPA risk genotypes, and increased risk of heart failure in the general population. JACC Heart Fail., 2016, 4(1), 78-87.
127. Ballantyne, C.M. Lipoprotein(a) and heart failure: another reason to study interventions in patients with very high levels of lipoprotein(a)? JACC Heart Fail., 2016, 4(1), 88-89.
128. Kamstrup, P.R.; Tybjærg-Hansen, A.; Nordestgaard, B.G. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J. Am. Coll. Cardiol., 2014, 63(5), 470-477.
129. Cioni, G.; Marcucci, R.; Gori, A.M.; Valente, S.; Giglioli, C.; Gensini, G.F.; Abbate, R.; Boddi, M. Increased homo-cysteine and lipoprotein(a) levels highlight systemic atherosclerotic burden in patients with a history of acute coronary syndromes. J. Vasc. Surg., 2016, 64(1), 163-170.
130. Song, P.; Seok, J.M.; Kim, W.S.; Lee, Y.T.; Kim, D.K.; Kim, G.M. Increased lipoprotein(a) is associated with poly-vascular disease in patients undergoing coronary artery bypass graft. Atherosclerosis, 2011, 219(1), 285-290.
131. Li, S.Y.; Gao, Y.; Ma, W.N.; Wang, H.C.; Zhou, G.; Guo, W.C.; Liu, Y.H. The relationship between serum lipoprotein (a) levels and ischemic stroke risk: a cohort study in the Chinese population. Inflammation, 2014, 37(3), 686-693.
132. Chakraborty, B.; Vishnoi, G.; Goswami, B.; Gowda, S.H.; Chowdhury, D.; Agarwal, S. Lipoprotein(a), ferritin, and albumin in acute phase reaction predicts severity and mortality of acute ischemic stroke in North Indian Patients. J. Stroke Cerebrovasc. Dis., 2013, 22(7), e159-e167.
133. Smolders, B.; Lemmens, R.; Thijs, V. Lipoprotein (a) and stroke: a meta-analysis of observational studies. Stroke, 2007, 38(6), 1959-1966.
134. Nave, A.H.; Lange, K.S.; Leonards, C.O.; Siegerink, B.; Doehner, W.; Landmesser, U.; Steinhagen-Thiessen, E.; Endres, M.; Ebinger, M. Lipoprotein (a) as a risk factor for ischemic stroke: a meta-analysis. Atherosclerosis, 2015, 242(2), 496-503.
135. Boden-Albala, B.; Kargman, D.E.; Lin, I.F.; Paik, M.C.; Sacco, R.L.; Berglund, L. Increased stroke risk and lipoprotein(a) in a multiethnic community: the Northern Manhattan Stroke Study. Cerebrovasc. Dis., 2010, 30(3), 237-243.
136. Jones, G.T.; Deng, M.; Hammond-Tooke, G.D.; McCormick, S.P.; van Rij, A.M. Increased plasma lipoprotein(a) found in large-artery atherosclerotic, but not small-artery occlusive, stroke. Clin. Chem., 2009, 55(10), 1888-1890.
137. Ohira, T.; Shahar, E.; Chambless, L.E.; Rosamond, W.D.; Mosley, T.H., Jr; Folsom, A.R. Risk factors for ischemic stroke subtypes: the Atherosclerosis Risk in Communities study. Stroke, 2006, 37(10), 2493-2498.
138. Sultan, S.M.; Schupf, N.; Dowling, M.M.; Deveber, G.A.; Kirton, A.; Elkind, M.S. Review of lipid and lipoprotein(a) abnormalities in childhood arterial ischemic stroke. Int. J. Stroke, 2014, 9(1), 79-87.
139. Akshintala, S.; Avery, R.A.; Murnick, J.; Verdun, N.; Diab, Y. Isolated midbrain ischemic infarct in association with hyperlipoproteinemia (a): a report of 2 adolescent patients. J. Pediatr. Hematol. Oncol., 2015, 37(4), 315-318.
140. Goldstein, L.B.; Adams, R.; Alberts, M.J.; Appel, L.J.; Brass, L.M.; Bushnell, C.D.; Culebras, A.; Degraba, T.J.; Gorelick, P.B.; Guyton, J.R.; Hart, R.G.; Howard, G.; Kelly-Hayes, M.; Nixon, J.V.; Sacco, R.L. Primary prevention of ischemic stroke: a guideline from the American Heart association/american stroke association stroke council: cosponsored by the atherosclerotic peripheral vascular disease interdisciplinary working group; cardiovascular nursing council; clinical cardiology council; nutrition, physical activity, and metabolism council; and the quality of care and outcomes research interdisciplinary working group: the american academy of neurology affirms the value of this guideline. Stroke, 2006, 37(6), 1583-1633.
141. Unal, E.; Mungan, S.; Bilen, S.; Karadag, Y.; Oztekin, N.; Bakir, F.; Ak, F. The effects of lipoprotein(a) and homocysteine on prognosis and risk factors in acute ischemic stroke. Int. J. Neurosci., 2013, 123(8), 532-536.
142. Ishikawa, S.; Kotani, K.; Kario, K.; Kayaba, K.; Gotoh, T.; Nakamura, Y.; Kajii, E. Inverse association between serum lipoprotein(a) and cerebral hemorrhage in the Japanese population. Thromb. Res., 2013, 131(2), e54-e58.
143. Gheini, M.R.; Jafari, E.; Ahmadi, A.; Togha, M.; Saidinia, S.; Moradi, M. Comparison of serum lipoprotein (a) level between non-cardioembolic ischemic stroke and traumatic brain injury. Clin. Lab., 2014, 60(5), 701-705.
144. Cinzia, F.; Daniela, P.; Elena, S.; Francesco, S.; Emilia, A.; Sandra, F.; Graziano, A.; Domenico, P.; Rosanna, A. Lipoprotein (a) [Lp(a)]: a possible link between migraine and stroke. Transl. Res., 2009, 153(1), 44-47.
145. Ray, L.; Khemka, V.K.; Behera, P.; Bandyopadhyay, K.; Pal, S.; Pal, K.; Basu, D.; Chakrabarti, S. Serum homocysteine, dehydroepiandrosterone sulphate and lipoprotein (a) in Alzheimers disease and vascular dementia. Aging Dis., 2013, 4(2), 57-64.
146. Panza, F.; D'Introno, A.; Colacicco, A.M.; Capurso, C.; Pichichero, G.; Capurso, S.A.; Capurso, A.; Solfrizzi, V. Lipid metabolism in cognitive decline and dementia. Brain Res. Brain Res. Rev., 2006, 51(2), 275-292.
147. Kunutsor, S.K.; Khan, H.; Nyyssönen, K.; Laukkanen, J.A. Is lipoprotein (a) protective of dementia? Eur. J. Epidemiol., 2016, 31(11), 1149-1152.
148. Zhang, W.; Zhang, X.A. Prognostic value of serum lipoprotein(a) levels in patients with acute ischemic stroke. Neuroreport, 2014, 25(4), 262-266.
149. Kotani, K.; Serban, M.C.; Penson, P.; Lippi, G.; Banach, M. Evidence-based assessment of lipoprotein(a) as a risk biomarker for cardiovascular diseases - Some answers and still many questions. Crit. Rev. Clin. Lab. Sci., 2016, 53(6), 370-378.
150. Yin, D.; Shao, P.; Liu, Y. Elevated lipoprotein (a) levels predict deep vein thrombosis in acute ischemic stroke patients. Neuroreport, 2016, 27(1), 39-44.
151. Ronald, J.; Rajagopalan, R.; Cerrato, F.; Nord, A.S.; Hatsukami, T.; Kohler, T.; Marcovina, S.; Heagerty, P.; Jarvik, G.P. Genetic variation in LPAL2, LPA, and PLG predicts plasma lipoprotein(a) level and carotid artery disease risk. Stroke, 2011, 42(1), 2-9.
152. Gardener, H.; Della Morte, D.; Elkind, M.S.; Sacco, R.L.; Rundek, T. Lipids and carotid plaque in the Northern Manhattan Study (NOMAS). BMC Cardiovasc. Disord., 2009, 9, 55.
153. Boras, J.; Ljubic, S.; Car, N.; Metelko, Z.; Petrovecki, M.; Lovrencic, M.V.; Reiner, Z. Lipoprotein(a) predicts progression of carotid artery intima-media thickening in patients with type 2 diabetes: A four-year follow-up. Wien. Klin. Wochenschr., 2010, 122(5-6), 159-164.
154. Knoflach, M.; Kiechl, S.; Penz, D.; Zangerle, A.; Schmidauer, C.; Rossmann, A.; Shingh, M.; Spallek, R.; Griesmacher, A.; Bernhard, D.; Robatscher, P.; Buchberger, W.; Draxl, W.; Willeit, J.; Wick, G. Cardiovascular risk factors and atherosclerosis in young women: atherosclerosis risk factors in female youngsters (ARFY study). Stroke, 2009, 40(4), 1063-1069.
155. Zhao, X.Q.; Hatsukami, T.S.; Hippe, D.S.; Sun, J.; Balu, N.; Isquith, D.A.; Crouse, J.R., III; Anderson, T.; Huston, J., III; Polissar, N.; O'Brien, K.; Yuan, C. Clinical factors associated with high-risk carotid plaque features as assessed by magnetic resonance imaging in patients with established vascular disease (from the AIM-HIGH Study). Am. J. Cardiol., 2014, 114(9), 1412-1419.
156. Spence, J.D. The role of lipoprotein(a) in the formation of arterial plaques, stenoses and occlusions. Can. J. Cardiol., 2010, 26(Suppl A), 37A-40A.
157. Bos, S.; Duvekot, M.H.; Touw-Blommesteijn, A.C.; Verhoeven, A.J.; Mulder, M.T.; Watts, G.F.; Sijbrands, E.J.; Roeters van Lennep, J.E. Lipoprotein (a) levels are not associated with carotid plaques and carotid intima media thickness in statin-treated patients with familial hypercholesterolemia. Atherosclerosis, 2015, 242(1), 226-229.
158. Calmarza, P.; Trejo, J.M.; Lapresta, C.; Lopez, P. Lack of association between carotid intima-media thickness and apolipoprotein (a) isoforms in a sample of Spanish general population. J. Cardiol., 2013, 61(5), 372-377.
159. Srámek, A.; Reiber, J.H.; Baak-Pablo, R.; Sturk, A.; Rosendaal, F.R. Lipoprotein(a) and ultrasonographically determined early atherosclerotic changes in the carotid and femoral artery. J. Thromb. Haemost., 2003, 1(2), 374-379.
160. Kotani, K.; Sakane, N. Carotid intima-media thickness in asymptomatic subjects with low lipoprotein(a) levels. J. Clin. Med. Res., 2012, 4(2), 130-134.
161. Ezhov, M.V.; Safarova, M.S.; Afanasieva, O.I.; Pogorelova, O.A.; Tripoten, M.I.; Adamova, I.Y.; Konovalov, G.A.; Balakhonova, T.V.; Pokrovsky, S.N. Specific Lipoprotein(a) apheresis attenuates progression of carotid intimamedia thickness in coronary heart disease patients with high lipoprotein(a) levels. Atheroscler. Suppl., 2015, 18, 163-169.
162. Laschkolnig, A.; Kollerits, B.; Lamina, C.; Meisinger, C.; Rantner, B.; Stadler, M.; Peters, A.; Koenig, W.; Stöckl, A.; Dähnhardt, D.; Böger, C.A.; Krämer, B.K.; Fraedrich, G.; Strauch, K.; Kronenberg, F. Lipoprotein (a) concentrations, apolipoprotein (a) phenotypes, and peripheral arterial disease in three independent cohorts. Cardiovasc. Res., 2014, 103(1), 28-36.
163. Hikita, H.; Shigeta, T.; Kimura, S.; Takahashi, A.; Isobe, M. Coronary artery disease severity and cardiovascular biomarkers in patients with peripheral artery disease. Int. J. Angiol., 2015, 24(4), 278-282.
164. Price, J.F.; Lee, A.J.; Rumley, A.; Lowe, G.D.; Fowkes, F.G. Lipoprotein (a) and development of intermittent claudication and major cardiovascular events in men and women: the Edinburgh Artery Study. Atherosclerosis, 2001, 157(1), 241-249.
165. Aboyans, V.; Criqui, M.H.; Denenberg, J.O.; Knoke, J.D.; Ridker, P.M.; Fronek, A. Risk factors for progression of peripheral arterial disease in large and small vessels. Circulation, 2006, 113(22), 2623-2629.
166. Kumakura, H.; Fujita, K.; Kanai, H.; Araki, Y.; Hojo, Y.; Kasama, S.; Iwasaki, T.; Ichikawa, S.; Nakashima, K.; Minami, K. High-sensitivity C-reactive protein, lipoprotein(a) and homocysteine are risk factors for coronary artery disease in japanese patients with peripheral arterial disease. J. Atheroscler. Thromb., 2015, 22(4), 344-354.
167. Ye, Z.; Ali, Z.; Klee, G.G.; Mosley, T.H., Jr; Kullo, I.J. Associations of candidate biomarkers of vascular disease with the ankle-brachial index and peripheral arterial disease. Am. J. Hypertens., 2013, 26(4), 495-502.
168. Hojo, Y.; Kumakura, H.; Kanai, H.; Iwasaki, T.; Ichikawa, S.; Kurabayashi, M. Lipoprotein(a) is a risk factor for aortic and mitral valvular stenosis in peripheral arterial disease. Eur. Heart J. Cardiovasc. Imaging, 2016, 17(5), 492-497.
169. Maca, T.; Mlekusch, W.; Doweik, L.; Budinsky, A.C.; Bischof, M.; Minar, E.; Schillinger, M. Influence and interaction of diabetes and lipoprotein (a) serum levels on mortality of patients with peripheral artery disease. Eur. J. Clin. Invest., 2007, 37(3), 180-186.
170. Giovanetti, F.; Gargiulo, M.; Laghi, L.; D'Addato, S.; Maioli, F.; Muccini, N.; Borghi, C.; Stella, A. Lipoprotein(a) and other serum lipid subfractions influencing primary patency after infrainguinal percutaneous transluminal angioplasty. J. Endovasc. Ther., 2009, 16(3), 389-396.
171. Maca, T.H.; Ahmadi, R.; Derfler, K.; Ehringer, H.; Gschwandtner, M.E.; Hörl, W.; Katzenschlager, R.; Müller-Knespel, E.; Koppensteiner, R.; Schneider, B.; Stümpflen, A.; Ugurluoglu, A.; Minar, E. Influence of lipoprotein(a) on restenosis after femoropopliteal percutaneous transluminal angioplasty in Type 2 diabetic patients. Diabet. Med., 2002, 19(4), 300-306.
172. Poller, W.C.; Dreger, H.; Morgera, S.; Berger, A.; Flessenkämper, I.; Enke-Melzer, K. Lipoprotein apheresis in patients with peripheral artery disease and hyperlipopro-teinemia(a). Atheroscler. Suppl., 2015, 18, 187-193.
173. Lippi, G.; Franchini, M.; Targher, G. Screening and therapeutic management of lipoprotein(a) excess: review of the epidemiological evidence, guidelines and recommendations. Clin. Chim. Acta, 2011, 412(11-12), 797-801.
174. Takagi, H.; Manabe, H.; Kawai, N.; Goto, S.N.; Umemoto, T. Circulating lipoprotein(a) concentrations and abdominal aortic aneurysm presence. Interact. Cardiovasc. Thorac. Surg., 2009, 9(3), 467-470.
175. Schillinger, M.; Domanovits, H.; Ignatescu, M.; Exner, M.; Bayegan, K.; Sedivy, R.; Polterauer, P.; Laggner, A.N.; Minar, E.; Kostner, K. Lipoprotein (a) in patients with aortic aneurysmal disease. J. Vasc. Surg., 2002, 36(1), 25-30.
176. Petersen, E.; Wågberg, F.; Angquist, K.A. Does lipoprotein(a) inhibit elastolysis in abdominal aortic aneurysms? Eur. J. Vasc. Endovasc. Surg., 2003, 26(4), 423-428.
177. Kotani, K.; Sahebkar, A.; Serban, M.C.; Ursoniu, S.; Mikhailidis, D.P.; Mariscalco, G.; Jones, S.R.; Martin, S.; Blaha, M.J.; Toth, P.P.; Rizzo, M.; Kostner, K.; Rysz, J.; Banach, M. Lipoprotein(a) levels in patients with abdominal aortic aneurysm: a systematic review and meta-analysis. Angiology, 2016. [Epub ahead of print].
178. Stather, P.W.; Sidloff, D.A.; Dattani, N.; Gokani, V.J.; Choke, E.; Sayers, R.D.; Bown, M.J. Meta-analysis and meta-regression analysis of biomarkers for abdominal aortic aneurysm. Br. J. Surg., 2014, 101(11), 1358-1372.
179. Scoble, J.E.; de Takats, D.; Ostermann, M.E.; Connolly, J.O.; Scott, N.R.; Beeso, J.A.; Poyser, K.H.; Peters, T.J.; Sherwood, R.A. Lipid profiles in patients with atherosclerotic renal artery stenosis. Nephron, 1999, 83(2), 117-121.
180. Paraskevas, K.I.; Hamilton, G.; Cross, J.M.; Mikhailidis, D.P. Atherosclerotic renal artery stenosis: association with emerging vascular risk factors. Nephron Clin. Pract., 2008, 108(1), c56-c66.
181. Athyros, V.G.; Katsiki, N.; Karagiannis, A.; Mikhailidis, D.P. Editorial: should chronic kidney disease be considered as a coronary heart disease equivalent? Curr. Vasc. Pharmacol., 2012, 10(3), 374-377.
182. Genest, J.; McPherson, R.; Frohlich, J.; Anderson, T.; Campbell, N.; Carpentier, A.; Couture, P.; Dufour, R.; Fodor, G.; Francis, G.A.; Grover, S.; Gupta, M.; Hegele, R.A.; Lau, D.C.; Leiter, L.; Lewis, G.F.; Lonn, E.; Mancini, G.B.; Ng, D.; Pearson, G.J.; Sniderman, A.; Stone, J.A.; Ur, E. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can. J. Cardiol., 2009, 25(10), 567-579.
183. Reiner, Z.; Catapano, A.L.; De Backer, G.; Graham, I.; Taskinen, M.R.; Wiklund, O.; Agewall, S.; Alegria, E.; Chapman, M.J.; Durrington, P.; Erdine, S.; Halcox, J.; Hobbs, R.; Kjekshus, J.; Filardi, P.P.; Riccardi, G.; Storey, R.F.; Wood, D. ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the european society of cardiology (ESC) and the european atherosclerosis society (EAS). Eur. Heart J., 2011, 32(14), 1769-1818.
184. Barter, P. Lipoprotein metabolism and CKD: overview. Clin. Exp. Nephrol., 2014, 18(2), 243-246.
185. Kronenberg, F. Causes and consequences of lipoprotein(a) abnormalities in kidney disease. Clin. Exp. Nephrol., 2014, 18(2), 234-237.
186. Aggarwal, H.K.; Jain, D.; Lathar, M.; Yadav, R.K.; Sawhney, A. Lipoprotein-A and carotid intima media thickness as cardiovascular risk factors in patients of chronic kidney disease. Ren. Fail., 2010, 32(6), 647-652.
187. Vaziri, N.D. Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences. Kidney Int., 2016, 90(1), 41-52.
188. Liu, J.; Rosner, M.H. Lipid abnormalities associated with end-stage renal disease. Semin. Dial., 2006, 19(1), 32-40.
189. Ikewaki, K. In vivo kinetic studies to further understand pathogenesis of abnormal lipoprotein metabolism in chronic kidney disease. Clin. Exp. Nephrol., 2014, 18(2), 261-264.
190. Kalra, O.P.; Khaira, A.; Gambhir, J.K.; Agarwal, S.; Bhargava, S.K. Lipoprotein (a) in chronic renal failure: effect of maintenance hemodialysis. Hemodial. Int., 2003, 7(4), 326-331.
191. Lin, J.; Khetarpal, S.A.; Terembula, K.; Reilly, M.P.; Wilson, F.P. Relation of atherogenic lipoproteins with estimated glomerular filtration rate decline: a longitudinal study. BMC Nephrol., 2015, 16, 130.
192. Yun, J.S.; Ahn, Y.B.; Song, K.H.; Yoo, K.D.; Park, Y.M.; Kim, H.W.; Ko, S.H. Lipoprotein(a) predicts a new onset of chronic kidney disease in people with Type 2 diabetes mellitus. Diabet. Med., 2016, 33(5), 639-643.
193. Rahman, M.; Yang, W.; Akkina, S.; Alper, A.; Anderson, A.H.; Appel, L.J.; He, J.; Raj, D.S.; Schelling, J.; Strauss, L.; Teal, V.; Rader, D.J. Relation of serum lipids and lipoproteins with progression of CKD: The CRIC study. Clin. J. Am. Soc. Nephrol., 2014, 9(7), 1190-1198.
194. Konishi, H.; Miyauchi, K.; Tsuboi, S.; Ogita, M.; Naito, R.; Dohi, T.; Kasai, T.; Tamura, H.; Okazaki, S.; Isoda, K.; Daida, H. Plasma lipoprotein(a) predicts major cardiovascular events in patients with chronic kidney disease who undergo percutaneous coronary intervention. Int. J. Cardiol., 2016, 205, 50-53.
195. Longenecker, J.C.; Klag, M.J.; Marcovina, S.M.; Liu, Y.M.; Jaar, B.G.; Powe, N.R.; Fink, N.E.; Levey, A.S.; Coresh, J. High lipoprotein(a) levels and small apolipoprotein(a) size prospectively predict cardiovascular events in dialysis patients. J. Am. Soc. Nephrol., 2005, 16(6), 1794-1802.
196. Fukunaga, N.; Anan, F.; Kaneda, K.; Nawata, T.; Saikawa, T.; Yoshimatsu, H. Lipoprotein (a) as a risk factor for silent cerebral infarction in hemodialysis patients. Metabolism, 2008, 57(10), 1323-1327.
197. Nasri, H.; Baradaran, A. Association of early atherosclerotic vascular changes with serum lipoprotein (a) in predialysis chronic renal failure and maintenance hemodialysis patients. Saudi J. Kidney Dis. Transpl., 2005, 16(2), 154-160.
198. Frostegård, J. Prediction and management of cardiovascular outcomes in systemic lupus erythematosus. Expert Rev. Clin. Immunol., 2015, 11(2), 247-253.
199. Prasad, M.; Hermann, J.; Gabriel, S.E.; Weyand, C.M.; Mulvagh, S.; Mankad, R.; Oh, J.K.; Matteson, E.L.; Lerman, A.; Lerman, A. Cardiorheumatology: cardiac involvement in systemic rheumatic disease. Nat. Rev. Cardiol., 2015, 12(3), 168-176.
200. Giles, J.T. Cardiovascular disease in rheumatoid arthritis: Current perspectives on assessing and mitigating risk in clinical practice. Best Pract. Res. Clin. Rheumatol., 2015, 29(4-5), 597-613.
201. Katsiki, N.; Anagnostis, P.; Athyros, V.G.; Karagiannis, A.; Mikhailidis, D.P. Psoriasis and vascular risk: an update. Curr. Pharm. Des., 2014, 20(39), 6114-6125.
202. Peters, M.J.; Symmons, D.P.; McCarey, D.; Dijkmans, B.A.; Nicola, P.; Kvien, T.K.; McInnes, I.B.; Haentzschel, H.; Gonzalez-Gay, M.A.; Provan, S.; Semb, A.; Sidiropoulos, P.; Kitas, G.; Smulders, Y.M.; Soubrier, M.; Szekanecz, Z.; Sattar, N.; Nurmohamed, M.T. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann. Rheum. Dis., 2010, 69(2), 325-331.
203. Govindan, K.P.; Basha, S.; Ramesh, V.; Kumar, C.N.; Swathi, S. A comparative study on serum lipoprotein (a) and lipid profile between rheumatoid arthritis patients and normal subjects. J. Pharm. Bioallied Sci., 2015, 7(Suppl. 1), S22-S25.
204. García-Gómez, C.; Bianchi, M.; de la Fuente, D.; Badimon, L.; Padró, T.; Corbella, E.; Pintó, X. Inflammation, lipid metabolism and cardiovascular risk in rheumatoid arthritis: A qualitative relationship? World J. Orthop., 2014, 5(3), 304-311.
205. Yoo, W.H. Dyslipoproteinemia in patients with active rheumatoid arthritis: effects of disease activity, sex, and menopausal status on lipid profiles. J. Rheumatol., 2004, 31(9), 1746-1753.
206. Wang, J.; Hu, B.; Kong, L.; Cai, H.; Zhang, C. Native, oxidized lipoprotein(a) and lipoprotein(a) immune complex in patients with active and inactive rheumatoid arthritis: plasma concentrations and relationship to inflammation. Clin. Chim. Acta, 2008, 390(1-2), 67-71.
207. Kerekes, G.; Szekanecz, Z.; Dér, H.; Sándor, Z.; Lakos, G.; Muszbek, L.; Csipö, I.; Sipka, S.; Seres, I.; Paragh, G.; Kappelmayer, J.; Szomják, E.; Veres, K.; Szegedi, G.; Shoenfeld, Y.; Soltész, P. Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity. J. Rheumatol., 2008, 35(3), 398-406.
208. Dursunoǧlu, D.; Evrengül, H.; Polat, B.; Tanriverdi, H.; Cobankara, V.; Kaftan, A.; Kiliç, M. Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis: serum levels and relationship to inflammation. Rheumatol. Int., 2005, 25(4), 241-245.
209. Gabay, C.; McInnes, I.B.; Kavanaugh, A.; Tuckwell, K.; Klearman, M.; Pulley, J.; Sattar, N. Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis. Ann. Rheum. Dis., 2016, 75(10), 1806-1812.
210. Müller, N.; Schulte, D.M.; Türk, K.; Freitag-Wolf, S.; Hampe, J.; Zeuner, R.; Schröder, J.O.; Gouni-Berthold, I.; Berthold, H.K.; Krone, W.; Rose-John, S.; Schreiber, S.; Laudes, M. IL-6 blockade by monoclonal antibodies inhibits apolipoprotein (a) expression and lipoprotein (a) synthesis in humans. J. Lipid Res., 2015, 56(5), 1034-1042.
211. McInnes, I.B.; Thompson, L.; Giles, J.T.; Bathon, J.M.; Salmon, J.E.; Beaulieu, A.D.; Codding, C.E.; Carlson, T.H.; Delles, C.; Lee, J.S.; Sattar, N. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. Ann. Rheum. Dis., 2015, 74(4), 694-702.
212. Hjeltnes, G.; Hollan, I.; Førre, O.; Wiik, A.; Lyberg, T.; Mikkelsen, K.; Agewall, S. Serum levels of lipoprotein(a) and E-selectin are reduced in rheumatoid arthritis patients treated with methotrexate or methotrexate in combination with TNF-α-inhibitor. Clin. Exp. Rheumatol., 2013, 31(3), 415-421.
213. Missala, I.; Kassner, U.; Steinhagen-Thiessen, E. A Systematic literature review of the association of lipoprotein(a) and autoimmune diseases and atherosclerosis. Int. J. Rheumatol., 2012, 2012, 480784.
214. Sari, R.A.; Polat, M.F.; Taysi, S.; Bakan, E.; Capoǧlu, I. Serum lipoprotein(a) level and its clinical significance in patients with systemic lupus erythematosus. Clin. Rheumatol., 2002, 21(6), 520-524.
215. Rhew, E.Y.; Manzi, S.M.; Dyer, A.R.; Kao, A.H.; Danchenko, N.; Barinas-Mitchell, E.; Sutton-Tyrrell, K.; McPherson, D.D.; Pearce, W.; Edmundowicz, D.; Kondos, G.T.; Ramsey-Goldman, R. Differences in subclinical cardiovascular disease between African American and Caucasian women with systemic lupus erythematosus. Transl. Res., 2009, 153(2), 51-59.
216. Szekanecz, Z.; Koch, A.E. Vascular involvement in rheumatic diseases: vascular rheumatology. Arthritis Res. Ther., 2008, 10(5), 224.
217. Karadag, O.; Calguneri, M.; Atalar, E.; Yavuz, B.; Akdogan, A.; Kalyoncu, U.; Bilgen, S.A.; Ozer, N.; Ertenli, A.I.; Ovunc, K.; Kiraz, S. Novel cardiovascular risk factors and cardiac event predictors in female inactive systemic lupus erythematosus patients. Clin. Rheumatol., 2007, 26(5), 695-699.
218. Lertratanakul, A.; Wu, P.; Dyer, A.R.; Kondos, G.; Edmundowicz, D.; Carr, J.; Ramsey-Goldman, R. Risk factors in the progression of subclinical atherosclerosis in women with systemic lupus erythematosus. Arthritis Care Res. (Hoboken), 2014, 66(8), 1177-1185.
219. Kiani, A.N.; Fishman, E.K.; Petri, M. Aortic valve calcification in systemic lupus erythematosus. Lupus, 2006, 15(12), 873-876.
220. Schanberg, L.E.; Sandborg, C; Barnhart, H.X.; Ardoin, S.P.; Yow, E.; Evans, G.W.; Mieszkalski, K.L.; Ilowite, N.T.; Eberhard, A.; Levy, D.M.; Kimura, Y.; von Scheven, E.; Silverman, E.; Bowyer, S.L.; Punaro, L.; Singer, N.G.; Sherry, D.D.; McCurdy, D.; Klein-Gitelman, M.; Wallace, C; Silver, R.; Wagner-Weiner, L.; Higgins, G.C.; Brunner, H.I.; Jung, L.; Soep, J.B.; Reed, A. Premature atherosclerosis in pediatric systemic lupus erythematosus: risk factors for increased carotid intima-media thickness in the atherosclerosis prevention in pediatric lupus erythematosus cohort. Arthritis Rheum., 2009, 60(5), 1496-1507.
221. Kiani, A.N.; Vogel-Claussen, J.; Magder, L.S.; Petri, M. Noncalcified coronary plaque in systemic lupus erythematosus. J. Rheumatol, 2010, 37(3), 579-584.
222. Sunitha, S.; Rajappa, M.; Thappa, D.M.; Chandrashekar, L.; Munisamy, M.; Revathy, G.; Priyadarssini, M. Comprehensive lipid tetrad index, atherogenic index and lipid peroxidation: Surrogate markers for increased cardiovascular risk in psoriasis. Indian J. Dermatol. Venereol. Leprol, 2015, 81(5), 464-471.
223. Ferretti, G.; Bacchetti, T.; Campanati, A.; Simonetti, O.; Liberati, G.; Offidani, A. Correlation between lipoprotein(a) and lipid peroxidation in psoriasis: role of the enzyme paraoxonase-1. Br. J. Dermatol, 2012, 166(1), 204-207.
224. Pietrzak, A.; Kadzielewski, J.; Janowski, K.; Roliński, J.; Krasowska, D.; Chodorowska, G.; Paszkowski, T.; Kapeć, E.; Jastrzebska, I.; Tabarkiewicz, J.; Lotti, T. Lipoprotein (a) in patients with psoriasis: associations with lipid profiles and disease severity. Int. J. Dermatol, 2009, 48(4), 379-387.
225. Coimbra, S.; Oliveira, H.; Reis, F.; Belo, L.; Rocha, S.; Quintanilha, A.; Figueiredo, A.; Teixeira, F.; Castro, E.; Rocha-Pereira, P.; Santos-Silva, A. Psoriasis therapy and cardiovascular risk factors: a 12-week follow-up study. Am. J. Clin. Dermatol, 2010, 11(6), 423-432.
226. Katsiki, N.; Athyros, V.G.; Karagiannis, A.; Wierzbicki, A.S.; Mikhailidis, D.P. Should we expand the concept of coronary heart disease equivalents? Curr. Opin. Cardiol, 2014, 29(4), 389-395.
227. Vonbank, A.; Saely, C.H.; Rein, P.; Zanolin, D.; Drexel, H. Lipoprotein (a), the metabolic syndrome and vascular risk in angiographied coronary patients. J. Clin. Endocrinol. Metab., 2016, 101(8), 3199-3203.
228. Gentile, M.; Iannuzzo, G.; Mattiello, A.; Marotta, G.; Iannuzzi, A.; Panico, S.; Rubba, P. Association between Lp (a) and atherosclerosis in menopausal women without metabolic syndrome. Biomarkers Med., 2016, 10(4), 397-402.
229. Sung, K.C.; Wild, S.H.; Byrne, CD. Lipoprotein (a), metabolic syndrome and coronary calcium score in a large occupational cohort. Nutr. Metab. Cardiovasc. Dis., 2013, 23(12), 1239-1246.
230. Bozbaş, H.; Yildirir, A.; Pirat, B.; Eroǧlu, S.; Korkmaz, M.E.; Atar, I.; Ulus, T.; Aydinalp, A.; Ozin, B.; Müderrisoǧlu, H. Increased lipoprotein(a) in metabolic syndrome: is it a contributing factor to premature atherosclerosis? Anadolu Kardiyol. Derg., 2008, 8(2), 111-115.
231. Bermúdez, V.; Rojas, J.; Salazar, J.; Bello, L.; Añez, R.; Toledo, A.; Chacín, M.; Aguirre, M.; Villalobos, M.; Chávez, M.; Martínez, M.S.; Torres, W.; Torres, Y.; Mejías, J.; Mengual, E.; Rojas, L.; Sánchez de Rosales, M.; Quevedo, A.; Cano, R.; Cabrera, M.; París, R.; Lubo, A.; Montiel, M.; Cano, C. Variations of lipoprotein(a) levels in the metabolic syndrome: a report from the Maracaibo City Metabolic Syndrome Prevalence Study. J. Diabetes. Res., 2013, 2013, 416451.
232. Muñoz-Torrero, J.F.; Rivas, D.; Alonso, R.; Crespo, L.; Costo, A.; Roman, M.; Martín, C.; Zamorano, J. Influence of lipoprotein (a) on inflammatory biomarkers in metabolic syndrome. South. Med. J., 2012, 105(7), 339-343.
233. Katsiki, N.; Athyros, V.G.; Karagiannis, A.; Mikhailidis, D.P. Characteristics other than the diagnostic criteria associated with metabolic syndrome: an overview. Curr. Vasc. Pharmacol., 2014, 12(4), 627-641.
234. Nikolic, D.; Katsiki, N.; Montalto, G.; Isenovic, E.R.; Mikhailidis, D.P.; Rizzo, M. Lipoprotein subfractions in metabolic syndrome and obesity: clinical significance and therapeutic approaches. Nutrients, 2013, 5(3), 928-948.
235. Katsiki, N.; Mikhailidis, D.P.; Mantzoros, C.S. Nonalcoholic fatty liver disease and dyslipidemia: An update. Metabolism, 2016, 65(8), 1109-1123.
236. Athyros, V.G.; Tziomalos, K.; Katsiki, N.; Doumas, M.; Karagiannis, A.; Mikhailidis, D.P. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. World J. Gastroenterol., 2015, 21(22), 6820-6834.
237. Nam, J.S.; Jo, S.; Kang, S.; Ahn, C.W.; Kim, K.R.; Park, J.S. Association between lipoprotein(a) and nonalcoholic fatty liver disease among Korean adults. Clin. Chim. Acta, 2016, 461, 14-18.
238. Yang, M.H.; Son, H.J.; Sung, J.D.; Choi, Y.H.; Koh, K.C.; Yoo, B.C.; Paik, S.W. The relationship between apolipoprotein E polymorphism, lipoprotein (a) and fatty liver disease. Hepatogastroenterology, 2005, 52(66), 1832-1835.
239. Lee, S.; Jin Kim, Y.; Yong Jeon, T.; Hoi Kim, H.; Woo Oh, S.; Park, Y.; Soo Kim, S. Obesity is the only independent factor associated with ultrasound-diagnosed non-alcoholic fatty liver disease: a cross-sectional case-control study. Scand. J. Gastroenterol., 2006, 41(5), 566-572.
240. Cankurtaran, M.; Tayfur, O.; Yavuz, B.B.; Geyik, S.; Akhan, O.; Arslan, S. Insulin resistance and metabolic syndrome in patients with NAFLD but without diabetes: effect of a 6 month regime intervention. Acta Gastroenterol. Belg., 2007, 70(3), 253-259.
241. Koruk, M.; Tayşi, S.; Savaş, M.C.; Yilmaz, O.; Akçay, F.; Karakök, M. Serum levels of acute phase proteins in patients with nonalcoholic steatohepatitis. Turk. J. Gastroenterol., 2003, 14(1), 12-17.
242. Katsiki, N.; Wierzbicki, A.S.; Mikhailidis, D.P. Erectile dysfunction and coronary heart disease. Curr. Opin. Cardiol., 2015, 30(4), 416-421.
243. Salavati, A.; Mehrsai, A.; Allameh, F.; Alizadeh, F.; Namdari, F.; Hosseinian, M.; Salimi, E.; Heidari, F.; Pourmand, G. Is serum uric acid level correlated with erectile dysfunction in coronary artery disease patients? Acta Med. Iran, 2016, 54(3), 173-175.
244. Eaton, C.B.; Liu, Y.L.; Mittleman, M.A.; Miner, M.; Glasser, D.B.; Rimm, E.B. A retrospective study of the relationship between biomarkers of atherosclerosis and erectile dysfunction in 988 men. Int. J. Impot. Res., 2007, 19(2), 218-225.
245. El-Latif, M.A.; Makhlouf, A.A.; Moustafa, Y.M.; Gouda, T.E.; Niederberger, C.S.; Elhanbly, S.M. Diagnostic value of nitric oxide, lipoprotein(a), and malondialdehyde levels in the peripheral venous and cavernous blood of diabetics with erectile dysfunction. Int. J. Impot. Res., 2006, 18(6), 544-549.
246. Doumas, M.; Lazaridis, A.; Katsiki, N.; Athyros, V. PDE-5 inhibitors: clinical points. Curr. Drug Targets, 2015, 16(5), 420-426.
247. Solomon, H.; Wierzbicki, A.S.; Lumb, P.J.; LambertHammill, M.; Jackson, G. Cardiovascular risk factors determine erectile and arterial function response to sildenafil. Am. J. Hypertens., 2006, 19(9), 915-919.
248. Sullivan, M.E.; Miller, MA.; Bell, C.R.; Jagroop, I.A.; Thompson, C.S.; Khan, MA.; Morgan, R.J.; Mikhailidis, D.P. Fibrinogen, lipoprotein (a) and lipids in patients with erectile dysfunction. A preliminary study. Int. Angiol., 2001, 20(3), 195-199.
249. Can, M.; Açikgöz, S.; Mungan, G.; Bayraktaroǧlu, T.; Koçak, E.; Güven, B.; Demirtas, S. Serum cardiovascular risk factors in obstructive sleep apnea. Chest, 2006, 129(2), 233-237.
250. Pac-Kożuchowska, E.; Krawiec, P.; Mroczkowska-Juchkiewicz, A.; Pawłowska-Kamieniak, A.; Kominek, K. Inflammatory and lipid-associated markers of cardiovascular diseases in children with first exacerbation of inflammatory bowel disease. Med. Sci. Monit., 2016, 22, 1534-1539.
251. Koutroubakis, I.E.; Malliaraki, N.; Vardas, E.; Ganotakis, E.; Margioris, A.N.; Manousos, O.N.; Kouroumalis, EA. Increased levels of lipoprotein (a) in Crohns disease: a relation to thrombosis? Eur. J. Gastroenterol. Hepatol, 2001, 13(12), 1415-1419.
252. van Bodegraven, A.A.; Meuwissen, S.G. Lipoprotein (a), thrombophilia and inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol, 2001, 13(12), 1407-1409.
253. Calabrò, R.S.; Pezzini, A.; Gervasi, G.; Pollicino, P.; Bramanti, P. Recurrent ischemic stroke in a patient with ulcerative colitis and high levels of lipoprotein (a). Blood Coagul Fibrinolysis, 2011, 22(6), 549-551.
254. Enkhmaa, B.; Anuurad, E.; Zhang, W.; Abbuthalha, A.; Li, X.D.; Dotterweich, W.; Pollard, R.B.; Asmuth, D.M.; Berglund, L. HIV disease activity as a modulator of lipoprotein(a) and allele-specific apolipoprotein(a) levels. Arterioscler. Thromb. Vasc. Biol., 2013, 33(2), 387-392.
255. Crook, M. The basis and management of metabolic abnormalities associated with cardiovascular risk in human immunodeficiency virus infection and its treatment. Ann. Clin. Biochem., 2007, 44(Pt 3), 219-231.
256. Egaña-Gorroño, L.; Martínez, E.; Escribà, T.; Calvo, M.; Gatell, J.M.; Arnedo, M. Association study of lipoprotein(a) genetic markers, traditional risk factors, and coronary heart disease in HIV-1-infected patients. Front. Immunol., 2012, 3, 367.
257. Stein, J.H. Dyslipidemia in the era of HIV protease inhibitors. Prog. Cardiovasc. Dis., 2003, 45(4), 293-304.
258. Velasquez, E.M.; Glancy, D.L. Cardiovascular disease in patients infected with the human immunodeficiency virus. J. La. State Med. Soc., 2003, 155(6), 314-324.
259. Mauss, S.; Berger, F.; Schmutz, G.; Henke, J.; Richter, W.O. Lipoprotein(a) in patients initiating antiretroviral therapy. HIV Med., 2008, 9(6), 415-420.
260. Piconi, S.; Parisotto, S.; Rizzardini, G.; Passerini, S.; Meraviglia, P.; Schiavini, M.; Niero, F.; Biasin, M.; Bonfanti, P.; Ricci, E.D.; Trabattoni, D.; Clerici, M. Atherosclerosis is associated with multiple pathogenic mechanisms in HIV-infected antiretroviral-naive or treated individuals. AIDS, 2013, 27(3), 381-389.